Veracyte, headquartered in South San Francisco, develops diagnostic products for various cancers and employs 815 people. The company went public in 2013 and offers tests like Afirma and Decipher.
Karin Eastham sold 4,590 shares of VCYT on 13 June at $26.66 per share, worth a total of $122K. They now own 13,907 VCYT shares, or a 25% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
